Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Brainomix Wins FDA Nod to Broaden Use of Stroke AI
OEM News

Brainomix Wins FDA Nod to Broaden Use of Stroke AI

A new feature lets physicians assess ischemic core volume from universally available non-contrast CT images through Brainomix 360.

Brainomix, a company focused on artificial intelligence (AI)-powered stroke imaging, has earned U.S. Food and Drug Administration (FDA) clearance for a new feature for its Brainomix 360 stroke solution.

The new, patented feature lets physicians assess ischemic core volume from universally available non-contrast CT (NCCT) images through Brainomix 360.

The company said the core volume feature was validated by leading U.S. stroke centers and showed equivalency to CT perfusion and MRI-derived core volume assessments. This addresses an unmet need in stroke triage, allowing expert-level insights to be gleaned from routinely available brain scans.

According to the company, Brainomix 360 is the only stroke AI imaging tool with a demonstrated impact on rates of stroke treatment. A real-world evaluation of stroke AI with national-level data from over 450,000 patients over three years found Brainomix 360 was related to an over 50% increase in mechanical thrombectomy rates.

“This key expansion of our Brainomix 360 platform marks a critical advancement in stroke imaging and reinforces our mission to transform stroke care through cutting-edge technology,” said Dr. Michalis Papadakis, co-founder and CEO at Brainomix. “Brainomix 360 empowers stroke teams by unlocking real-time, high-precision insights that can help expand patient access to life-changing treatments, including both thrombolysis and mechanical thrombectomy, for use up to 24 hours after stroke onset.”

In February, Brainomix and Medtronic Neurovascular began a partnership to boost stroke care for Western European patients by integrating AI solutions into clinical practices.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters